Prelude Capital Management’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Prelude Capital Management’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-48,757	Closed	-$2.27M	–	1477
2023 Q2	$2.27M	Buy	+48,757	New	+$1.69M	0.15%	176
2022 Q4	–	Sell	-15,842	Closed	-$321K	–	1757
2022 Q3	$321K	Buy	15,842 +1,769	+13%	+$32.2K	0.01%	841
2022 Q2	$218K	Sell	14,073 -625	-4%	-$10.7K	0.01%	1256
2022 Q1	$281K	Buy	+14,698	New	+$262K	0.01%	1101

Prelude Capital Management's DICE Position: Q3 2023 in Review

Prelude Capital Management sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 48,757 shares — an estimated $2.27M sold.

Prelude Capital Management first reported a position in DICE in Q1 2022 and held it in 4 quarters. The position peaked at $2.27M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

Prelude Capital Management reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Prelude Capital Management sold 48,757 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $2.27M.
Prelude Capital Management first reported a position in DICE Therapeutics, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
Prelude Capital Management's DICE Therapeutics, Inc. Common Stock position peaked at $2.27M in Q2 2023.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Prelude Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.